NASDAQ:EPRX Eupraxia Pharmaceuticals Q2 2025 Earnings Report $6.60 +0.12 (+1.84%) As of 09:45 AM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Eupraxia Pharmaceuticals EPS ResultsActual EPS-$0.26Consensus EPS -$0.21Beat/MissMissed by -$0.05One Year Ago EPSN/AEupraxia Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AEupraxia Pharmaceuticals Announcement DetailsQuarterQ2 2025Date8/12/2025TimeBefore Market OpensConference Call DateTuesday, August 12, 2025Conference Call Time7:00AM ETConference Call ResourcesPress ReleaseEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release Eupraxia Pharmaceuticals Earnings HeadlinesEupraxia Pharmaceuticals Inc.: Eupraxia Pharmaceuticals Reports Symptom Response Data from its Ongoing Phase 1b/2a RESOLVE Trial, Including New Data on Odynophagia (Painful ...16 minutes ago | finanznachrichten.deEupraxia Pharmaceuticals Reports Symptom Response Data from its Ongoing Phase 1b/2a RESOLVE Trial, Including New Data on Odynophagia (Painful Swallowing) in Eosinophilic ...16 minutes ago | theglobeandmail.comReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.August 13 at 1:00 AM | Base Camp Trading (Ad)Eupraxia Pharmaceuticals Reports Symptom Response Data from its Ongoing Phase 1b/2a RESOLVE Trial, Including New Data on Odynophagia (Painful Swallowing) in Eosinophilic Esophagitis Patients1 hour ago | globenewswire.comEupraxia Pharmaceuticals Inc.: Eupraxia Pharmaceuticals Reports Second Quarter 2026 Financial ResultsAugust 12 at 1:44 PM | finanznachrichten.deEupraxia Pharmaceuticals Reports Second Quarter 2026 Financial ResultsAugust 11 at 5:31 PM | financialpost.comFSee More Eupraxia Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Eupraxia Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Eupraxia Pharmaceuticals and other key companies, straight to your email. Email Address About Eupraxia PharmaceuticalsEupraxia Pharmaceuticals (NASDAQ:EPRX), Inc. (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus. Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline. The company has established preclinical programs targeting additional autoimmune indications and is preparing to initiate subsequent trials as it builds clinical proof-of-concept for its Treg-focused approach. Eupraxia’s management team comprises seasoned professionals with expertise in immunology, drug development and regulatory affairs. The leadership is committed to leveraging decades of collective experience in biopharma to guide the company’s progression from early-stage research toward potential regulatory milestones and commercial readiness. As a publicly traded company on NASDAQ, Eupraxia Pharmaceuticals aims to deliver innovative, first-in-class treatments that address unmet medical needs in chronic immune-mediated conditions.View Eupraxia Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Franco-Nevada Earnings: Gold Is Rallying, But Does the Stock Even Care?Nebius’ Q2 Beat Shows the AI Bottleneck Is Capacity, Not DemandCoreWeave's $129 Billion AI Backlog Changes the Bull CaseGE Vernova’s AI Power Boom Faces a Profit TestCardinal Health Earnings: Can Perfection Get Priced In Twice?Legacy Jet Builders Stall While Embraer Accelerates to New HighsFastly’s Q2 Rally Shows Investors Are Buying the Edge AI Turnaround Upcoming Earnings BHP Group (8/17/2026)Palo Alto Networks (8/17/2026)Home Depot (8/18/2026)Medtronic (8/18/2026)Keysight Technologies (8/18/2026)Lowe's Companies (8/19/2026)TJX Companies (8/19/2026)Target (8/19/2026)Analog Devices (8/19/2026)NetEase (8/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
